GENFIT Stock Euronext Paris
Equities
FR0004163111
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
||
3.205 EUR | 0.00% |
Sales 2024 * | 89.63M 95.99M | Sales 2025 * | 48.78M 52.24M | Capitalization | 160M 171M |
---|---|---|---|---|---|
Net income 2024 * | 15M 16.06M | Net income 2025 * | -21M -22.49M | EV / Sales 2024 * | 1.47 x |
Net cash position 2024 * | 27.6M 29.56M | Net cash position 2025 * | 44.9M 48.08M | EV / Sales 2025 * | 2.35 x |
P/E ratio 2024 * |
6.83
x | P/E ratio 2025 * |
24.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.77% |
Latest transcript on GENFIT
Managers | Title | Age | Since |
---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 56 | 18-04-30 |
Founder | 68 | 99-08-31 | |
Thomas Baetz
DFI | Director of Finance/CFO | 50 | 21-04-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 21-03-03 | |
Founder | 68 | 99-08-31 | |
Founder | 52 | 99-09-14 |
1st Jan change | Capi. | |
---|---|---|
+4.09% | 43.84B | |
+47.81% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |